Alector enters the second half of 2026 as a fundamentally different company than the one that went public seven years ago: after three clinical program failures wiped out its partnerships with AbbVie and GSK, it now holds no active clinical trials and is financing a preclinical-only pipeline, with its final collaboration slated to terminate on January 2, 2027. The second-quarter print, released August 6, showed a narrowing net loss of $23.0 million on $3.3 million of collaboration revenue, both down sharply from a year earlier, as the company cut deep into its cost base after dismissing roughly 47 percent of its workforce last October and another 13 percent the prior March. The equity transaction of the quarter is not the operating statement but the balance sheet, where cash and marketable securities fell to $172.8 million and stockholders' equity turned negative for the first time, at negative $9.97 million.
The market is not yet pricing the full accounting consequence of GSK's exit. The company still carries $162.9 million of deferred revenue on its books tied to development services under the terminated GSK agreement, revenue that management expects to recognize over the wind-down of the programs that have now been discontinued. Our reading is that much of this deferred balance is at risk of reversal or impairment once the 180-day termination notice period runs out, which would push the already-negative equity position deeper and accelerate the need for the external capital the company has telegraphed through a fresh $125 million at-the-market facility and a $400 million shelf. The equity today is a call option on a preclinical portfolio led by the Alector Brain Carrier platform, not a going concern value.
The single load-bearing risk is capital adequacy, and the falsifiable clock is the next twelve to eighteen months: the company's $172.8 million of liquidity is guided to fund operations through 2027, but that runway assumes the deferred revenue recognition pattern holds and that no material new cost emerges from the GSK wind-down, which management has already flagged is outside its control. The next data point that tests this thesis is the first-quarter 2027 announcement, when both the GSK termination and the repayment of the Hercules debt are fully reflected, and when the company needs to demonstrate it can reach an IND filing for AL137 without first tapping the ATM or issuing equity that dilutes the current 111.7 million shares outstanding.